
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) related to its sale to SERB Pharmaceuticals. Under the terms of the proposed transaction, Y-mAbs shareholders will receive $8.60 in cash per share.
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) related to its sale to SERB Pharmaceuticals. Under the terms of the proposed transaction, Y-mAbs shareholders will receive $8.60 in cash per share.